The beauty medical device specialist CLASSYS announced on the 11th that it recorded its highest-ever performance in both revenue and operating profit for the second quarter of this year.
The second quarter, ahead of summer, is a peak season when the demand for beauty medical treatment equipment increases. During this period, sales of medical devices and consumables, including the main product 'Shrinky,' which uses ultrasound to enhance skin elasticity, surged.
CLASSYS's revenue for the second quarter of this year reached 83.3 billion won, an increase of 42% compared to the same period last year, while operating profit rose 38% year-on-year to 43 billion won. The operating profit margin reached 52%.
This is the first time the company's quarterly revenue has surpassed 80 billion won, and it was noted that it has broken both revenue and operating profit records for six consecutive quarters. Cumulative operating profit for the first half of the year stood at 81.8 billion won, exceeding 90% of last year's annual operating profit.
Sales of both equipment and consumables increased. In the second quarter, equipment sales amounted to 45.5 billion won, a 47% increase compared to the same period last year, while consumable sales rose to 35.2 billion won, reflecting a 35% year-on-year increase.
A representative from CLASSYS noted, 'The second quarter is the seasonal peak for equipment sales,' adding that 'the flagship product Shrinky Universe continues to maintain a steady high-growth trend, and the market penetration rate of volumetric fillers is also accelerating.' He explained that 'the growth in consumables sales is continuing year-on-year, driven by the increase in equipment installations, the spread of non-invasive treatment trends, and high consumer satisfaction.'
Currently, the Shrinky series (known internationally as Ultraformer) has surpassed cumulative global sales of 19,000 units and has demonstrated competitiveness in terms of safety and effectiveness with over 5 million high treatment numbers each year. Volumetric fillers have sold more than 2,000 units in the global market.
The company recently officially launched the micro-needle radiofrequency (MNRF) device 'Qudessy,' which combines invasive and non-invasive methods. The company stated, 'We anticipate that the effect of new product launches in the second half will be added,' and added, 'Based on synergy between products and differentiated marketing strategies, we will continue to expand our presence in the global market.'